Poolbeg makes excellent progress post IPO and momentum building
Poolbeg Pharma PLC (AIM:POLB) Results to 31 December 2021
Poolbeg Pharma PLC (AIM: POLB) Artificial Intelligence deal with OneThree Biotech
New treatments for infectious disease to be identified through analysis of human challenge trial data
Poolbeg Pharma PLC (POLB.L) Confirmation of vaccine platform licence execution
31 January 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, confirms that it has signed the licence
Poolbeg Pharma PLC (POLB.L) Exclusive license of RNA-based immunotherapy asset
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
Poolbeg Pharma (LSE:POLB) Year in (Video) Review 2021
Targeting the growing infectious disease market, we are developing multiple assets quickly to Phase II ready with plans to monetise early to Big Pharma. POLB spun out of Open Orphan
Share Talk catches up with CEO Jeremy Skillington, Poolbeg Pharma (LON: POLB) Interview
Share Talk caught up with our CEO to discuss yesterday’s announcement on #POLB’s has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full
Poolbeg Pharma (POLB.L) agrees terms to develop an oral vaccine delivery platform
16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet,
Poolbeg Pharma PLC (POLB.L) signs option for new vaccine candidate
Poolbeg signs Option Agreement with University College Dublin for a Melioidosis Vaccine candidate, MelioVac, and a licence to evaluate 5 other infectious disease portfolio assets
Poolbeg Pharma PLC (POLB.L) Scientific Advisory Board Appointment
US infectious diseases expert, Professor Daniel Hoft, joins Scientific Advisory Board 25 November 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a
Poolbeg Pharma PLC (POLB.L) Update on POLB 001 Clinical Development
Rapidly progressing towards LPS challenge study
Poolbeg Pharma PLC (POLB.L) PredictViral™ Patent update
14 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new
